1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

ASCO 2025 Meeting
ASCO 2025 Meeting (Alaric DeArment)

Merck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago raised some questions from the presentation’s discussant about the small number of patients treated to date and the fact that they were not very heavily pretreated.

Key Takeaways
  • Data from Merck’s Phase II/III study of zilo-V in DLBCL presented at ASCO showed improvements in overall response and complete response rates when added to rituximab, gemcitabine and oxaliplatin (R-GemOx).

The data presented on 30 May were from the first part of a two-part trial that compared zilo-V combined with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Therapy Areas

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.

AstraZeneca Scores FDA Win For Imfinzi In Perioperative Stomach Cancer

 
• By Alaric DeArment

The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.

Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’

 
• By Manas Mishra

Satellos is moving to start a double-blinded Phase II trial of its experimental Duchenne muscular dystrophy candidate that looks to mimic the effects of dystrophin on muscle stem cells.